白蛋白紫杉醇与紫杉醇注射液联合卡铂治疗宫颈癌的临床观察

Clinical Observation on Albumin Paclitaxel Combined with Carboplatin and Paclitaxel Injection Combined with Carboplatin in the Treatment of Cervical Cancer

目的比较白蛋白紫杉醇与紫杉醇注射液联合卡铂治疗宫颈癌的临床疗效。方法将98例宫颈癌患者随机分为白蛋白紫杉醇组和紫杉醇注射液组,各49例。白蛋白紫杉醇组采用白蛋白紫杉醇联合卡铂方案静脉化疗,紫杉醇注射液组采用紫杉醇注射液联合卡铂方案静脉化疗。比较两组的疗效和化疗不良反应。结果白蛋白紫杉醇组的治疗总有效率为73.47%,与紫杉醇注射液组的65.31%比较差异无统计学意义(P>0.05)。白蛋白紫杉醇组的胃肠道反应、骨髓抑制发生率显著低于紫杉醇注射液组(P <0.05)。结论与紫杉醇注射液联合卡铂相比,白蛋白紫杉醇联合卡铂治疗宫颈癌的安全性更为理想。

Objective To compare the clinical efficacy of albumin paclitaxel combined with carboplatin and paclitaxel injection combined with carboplatin in the treatment of cervical cancer.Methods 98 patients with cervical cancer were randomly divided into albumin paclitaxel group and paclitaxel injection group,with 49 cases in each group.Albumin paclitaxel group used albumin paclitaxel combined with carboplatin for intravenous chemotherapy.Paclitaxel injection group used paclitaxel injection combined with carboplatin for intravenous chemotherapy.The efficacy and adverse reactions of chemotherapy were compared between the two groups.Results The total effective rate of albumin paclitaxel group was 73.47%,which had no statistical difference with 65.31%of paclitaxel injection group(P>0.05).The incidences of gastrointestinal reaction and bone marrow suppression in albumin paclitaxel group were significantly lower than those in paclitaxel injection group(P<0.05).Conclusions Compared with paclitaxel injection combined with carboplatin,albumin paclitaxel combined with carboplatin has more ideal safety.